JP5771123B2 - プロフィラグリンｃ末端ドメイン特異的抗体及びその用途 - Google Patents
プロフィラグリンｃ末端ドメイン特異的抗体及びその用途 Download PDFInfo
- Publication number
- JP5771123B2 JP5771123B2 JP2011245483A JP2011245483A JP5771123B2 JP 5771123 B2 JP5771123 B2 JP 5771123B2 JP 2011245483 A JP2011245483 A JP 2011245483A JP 2011245483 A JP2011245483 A JP 2011245483A JP 5771123 B2 JP5771123 B2 JP 5771123B2
- Authority
- JP
- Japan
- Prior art keywords
- terminal domain
- gene
- filaggrin
- abnormality
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 101710088660 Filaggrin Proteins 0.000 claims description 40
- 210000004899 c-terminal region Anatomy 0.000 claims description 34
- 230000005856 abnormality Effects 0.000 claims description 28
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 24
- 201000008937 atopic dermatitis Diseases 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 23
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 12
- 210000000434 stratum corneum Anatomy 0.000 claims description 10
- 102100028314 Filaggrin Human genes 0.000 description 26
- 210000003491 skin Anatomy 0.000 description 25
- 108090000623 proteins and genes Proteins 0.000 description 19
- 230000035772 mutation Effects 0.000 description 12
- 108700041153 Filaggrin Proteins Proteins 0.000 description 8
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 8
- 230000005861 gene abnormality Effects 0.000 description 8
- 238000010186 staining Methods 0.000 description 8
- 239000002671 adjuvant Substances 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 239000002390 adhesive tape Substances 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- HSTOKWSFWGCZMH-UHFFFAOYSA-N 3,3'-diaminobenzidine Chemical compound C1=C(N)C(N)=CC=C1C1=CC=C(N)C(N)=C1 HSTOKWSFWGCZMH-UHFFFAOYSA-N 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 239000003593 chromogenic compound Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 238000012744 immunostaining Methods 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 230000037311 normal skin Effects 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- 229920000298 Cellophane Polymers 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010076876 Keratins Proteins 0.000 description 2
- 102000011782 Keratins Human genes 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000023514 Barrett esophagus Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 108010075526 keratohyalin Proteins 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000036620 skin dryness Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6881—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from skin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/20—Dermatological disorders
- G01N2800/202—Dermatitis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Priority Applications (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011245483A JP5771123B2 (ja) | 2011-11-09 | 2011-11-09 | プロフィラグリンｃ末端ドメイン特異的抗体及びその用途 |
| ES12848401.1T ES2650733T3 (es) | 2011-11-09 | 2012-11-08 | Anticuerpo específico para el dominio C-terminal de la profilagrina y su uso |
| PCT/JP2012/079015 WO2013069741A1 (ja) | 2011-11-09 | 2012-11-08 | プロフィラグリンc末端ドメイン特異的抗体及びその用途 |
| KR1020147011999A KR102025446B1 (ko) | 2011-11-09 | 2012-11-08 | 프로필라그린 c 말단 도메인 특이적 항체 및 그의 용도 |
| US14/356,985 US20140287431A1 (en) | 2011-11-09 | 2012-11-08 | Antibody specific to profilaggrin c-terminal domain, and use thereof |
| CN201280066201.0A CN104039827B (zh) | 2011-11-09 | 2012-11-08 | 丝聚合蛋白原c末端结构域特异性抗体及其用途 |
| EP12848401.1A EP2778174B1 (en) | 2011-11-09 | 2012-11-08 | Antibody specific to profilaggrin c-terminal domain, and use thereof |
| HK15102350.3A HK1201856B (en) | 2011-11-09 | 2012-11-08 | Antibody specific to profilaggrin c-terminal domain, and use thereof |
| US16/136,929 US20190079080A1 (en) | 2011-11-09 | 2018-09-20 | Antibody specific to profilaggrin c-terminal domain, and use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011245483A JP5771123B2 (ja) | 2011-11-09 | 2011-11-09 | プロフィラグリンｃ末端ドメイン特異的抗体及びその用途 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014014846A Division JP5943945B2 (ja) | 2014-01-29 | 2014-01-29 | プロフィラグリンｃ末端ドメイン特異的抗体及びその用途 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013100249A JP2013100249A (ja) | 2013-05-23 |
| JP2013100249A5 JP2013100249A5 (enExample) | 2013-08-08 |
| JP5771123B2 true JP5771123B2 (ja) | 2015-08-26 |
Family
ID=48290111
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011245483A Active JP5771123B2 (ja) | 2011-11-09 | 2011-11-09 | プロフィラグリンｃ末端ドメイン特異的抗体及びその用途 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20140287431A1 (enExample) |
| EP (1) | EP2778174B1 (enExample) |
| JP (1) | JP5771123B2 (enExample) |
| KR (1) | KR102025446B1 (enExample) |
| CN (1) | CN104039827B (enExample) |
| ES (1) | ES2650733T3 (enExample) |
| WO (1) | WO2013069741A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8956859B1 (en) | 2010-08-13 | 2015-02-17 | Aviex Technologies Llc | Compositions and methods for determining successful immunization by one or more vaccines |
| WO2020076770A1 (en) * | 2018-10-08 | 2020-04-16 | Yale University | Selective binding and aggregation of human keratin in the skin barrier using human filaggrin subdomains sd67 and sd150 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4162259B2 (ja) * | 1991-04-26 | 2008-10-08 | ビオメリュー・ソシエテ・アノニム | リウマチ性関節炎抗体により認識される抗原、抗原製剤及びその適用方法 |
| CA2570887C (en) * | 2004-06-18 | 2014-09-16 | Genentech, Inc. | Tumor treatment |
| GB0525492D0 (en) * | 2005-12-15 | 2006-01-25 | Univ Dundee | Filaggrin |
| JP2007217325A (ja) * | 2006-02-16 | 2007-08-30 | Kose Corp | プロフィラグリン及び／又はフィラグリン産生促進剤 |
| WO2011068166A1 (ja) * | 2009-12-03 | 2011-06-09 | 株式会社資生堂 | ブレオマオシン水解酵素の活性を指標としたアトピー性皮膚炎による乾燥肌改善剤のスクリーニング方法 |
-
2011
- 2011-11-09 JP JP2011245483A patent/JP5771123B2/ja active Active
-
2012
- 2012-11-08 EP EP12848401.1A patent/EP2778174B1/en active Active
- 2012-11-08 KR KR1020147011999A patent/KR102025446B1/ko not_active Expired - Fee Related
- 2012-11-08 US US14/356,985 patent/US20140287431A1/en not_active Abandoned
- 2012-11-08 CN CN201280066201.0A patent/CN104039827B/zh active Active
- 2012-11-08 ES ES12848401.1T patent/ES2650733T3/es active Active
- 2012-11-08 WO PCT/JP2012/079015 patent/WO2013069741A1/ja not_active Ceased
-
2018
- 2018-09-20 US US16/136,929 patent/US20190079080A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN104039827A (zh) | 2014-09-10 |
| EP2778174B1 (en) | 2017-11-01 |
| WO2013069741A1 (ja) | 2013-05-16 |
| EP2778174A4 (en) | 2015-06-24 |
| US20190079080A1 (en) | 2019-03-14 |
| HK1201856A1 (en) | 2015-09-11 |
| CN104039827B (zh) | 2016-12-14 |
| KR20140089366A (ko) | 2014-07-14 |
| KR102025446B1 (ko) | 2019-09-25 |
| JP2013100249A (ja) | 2013-05-23 |
| ES2650733T3 (es) | 2018-01-22 |
| EP2778174A1 (en) | 2014-09-17 |
| US20140287431A1 (en) | 2014-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Nguyen et al. | Antibodies against keratinocyte antigens other than desmogleins 1 and 3 can induce pemphigus vulgaris–like lesions | |
| Fresquet et al. | Identification of a major epitope recognized by PLA2R autoantibodies in primary membranous nephropathy | |
| US7803553B2 (en) | Methods of use of antibodies which recognize a protease cleavage site of an LAP fragment of TGF-β | |
| WO2005052593A1 (en) | Detection | |
| CA2105903A1 (en) | Methods and compositions for the detection of soluble .beta.-amyloid peptide | |
| JP2014521098A (ja) | 病理学バイオマーカーアッセイ | |
| Barascuk et al. | A MMP derived versican neo-epitope is elevated in plasma from patients with atherosclerotic heart disease | |
| JP2007277263A (ja) | カルボキシメチル化タンパク質に対する抗体 | |
| Reese-Petersen et al. | Evaluation of a novel biomarker of type XXVIII collagen formation, PRO-C28, in samples from cancer and heart failure with preserved ejection fraction patients | |
| JP5771123B2 (ja) | プロフィラグリンｃ末端ドメイン特異的抗体及びその用途 | |
| CN103183726B (zh) | 衍生自人bplp蛋白的肽、编码所述肽的多核苷酸和针对所述肽的抗体 | |
| JPH11242026A (ja) | 腎疾患の検査方法 | |
| JP5943945B2 (ja) | プロフィラグリンｃ末端ドメイン特異的抗体及びその用途 | |
| JP2011226882A (ja) | 泌尿器系疾患マーカー及びその抗体、並びに泌尿器系疾患診断用キット | |
| Chen et al. | High expression level of homocitrulline is correlated with seborrheic keratosis and skin aging | |
| JP4560314B2 (ja) | 中性アミノ酸トランスポーターによる癌の検出法、及びそのためのキット | |
| HK1201856B (en) | Antibody specific to profilaggrin c-terminal domain, and use thereof | |
| JP2648952B2 (ja) | 種々の病理的状態に於いてｐｓ２遺伝子から特異的に発現される蛋白質及びその断片、該蛋白質及び／又はその断片から得られる抗体、並びに病理的状態に対する検出、診断及び治療への該蛋白質、その断片及び抗体の適用 | |
| EP2918600A1 (en) | Novel peptide and use thereof | |
| JP2915530B2 (ja) | ラミニン フラグメント | |
| Staab-Weijnitz et al. | Assessment of Collagen in Translational Models of Lung Research | |
| JP4423426B2 (ja) | アドレノメデュリン前駆体ｃ末端ペプチドの濃度の上昇を循環器疾患又は炎症性疾患の指標とする方法 | |
| JP6183920B2 (ja) | 腎炎の病変部位の検査方法およびそのための試薬 | |
| KR20050083567A (ko) | 육모활성 평가방법 | |
| JP5354158B2 (ja) | 抗デカン酸修飾型グレリン抗体、デカン酸修飾型グレリン測定方法、およびデカン酸修飾型グレリン分離回収方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130607 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130607 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20130607 |
|
| A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20130710 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130723 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20131029 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20140128 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140129 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20140128 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20140414 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20140606 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150202 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150527 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150626 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5771123 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |